Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Tremblay

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Comparative Effectiveness Research|January 18, 2023
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturityBart Heeg, Andre Verhoek, Gabriel Tremblay, et al.
Advances in Therapy|January 23, 2025
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical TrialsKhashayar Azimpour, Patricia Dorling, Irene Koulinska, et al.
NPJ Digital Medicine|April 9, 2025
A group concept mapping study of stakeholder perspectives on digital therapeutics economic value driversYoann Sapanel, L Martin Cloutier, Gabriel Tremblay, et al.
Value in Health Regional Issues|October 9, 2018
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in RussiaGabriel Tremblay, Vasiliki Chounta, James Piercy, et al.
Journal of Comparative Effectiveness Research|June 1, 2018
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonistsMike Dolph, Anuja Roy, Menaka Bhor, et al.
Plos One|May 13, 2022
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myelomaPatrick Daniele, Carla Mamolo, Joseph C Cappelleri, et al.
Future Oncology (London, England)|April 21, 2023
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myelomaPatrick Daniele, Carla Mamolo, Joseph C Cappelleri, et al.
Gastro Hep Advances|August 12, 2024
Potassium-Competitive Acid Blocker and Proton Pump Inhibitor-Based Regimens for First-Line <i>Helicobacter pylori</i> Eradication: A Network Meta-AnalysisPeter Malfertheiner, Steven F Moss, Patrick Daniele, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Projected impact of a plant-derived vaccine on the burden of seasonal influenza in CanadaLauren Ramjee, William Lemay, Nesrin Vurgun, et al.
Therapeutic Advances in Gastroenterology|June 30, 2023
Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of <i>Helicobacter pylori</i> infectionSteven F Moss, William D Chey, Patrick Daniele, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Comparative Effectiveness Research|January 18, 2023
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturityBart Heeg, Andre Verhoek, Gabriel Tremblay, et al.
Advances in Therapy|January 23, 2025
Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical TrialsKhashayar Azimpour, Patricia Dorling, Irene Koulinska, et al.
NPJ Digital Medicine|April 9, 2025
A group concept mapping study of stakeholder perspectives on digital therapeutics economic value driversYoann Sapanel, L Martin Cloutier, Gabriel Tremblay, et al.
Value in Health Regional Issues|October 9, 2018
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in RussiaGabriel Tremblay, Vasiliki Chounta, James Piercy, et al.
Journal of Comparative Effectiveness Research|June 1, 2018
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonistsMike Dolph, Anuja Roy, Menaka Bhor, et al.
Plos One|May 13, 2022
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myelomaPatrick Daniele, Carla Mamolo, Joseph C Cappelleri, et al.
Future Oncology (London, England)|April 21, 2023
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myelomaPatrick Daniele, Carla Mamolo, Joseph C Cappelleri, et al.
Gastro Hep Advances|August 12, 2024
Potassium-Competitive Acid Blocker and Proton Pump Inhibitor-Based Regimens for First-Line <i>Helicobacter pylori</i> Eradication: A Network Meta-AnalysisPeter Malfertheiner, Steven F Moss, Patrick Daniele, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Projected impact of a plant-derived vaccine on the burden of seasonal influenza in CanadaLauren Ramjee, William Lemay, Nesrin Vurgun, et al.
Therapeutic Advances in Gastroenterology|June 30, 2023
Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of <i>Helicobacter pylori</i> infectionSteven F Moss, William D Chey, Patrick Daniele, et al.
Pageof 6